Advertisement

Topics

PARP Inhibitor and NO-Donor Dual Prodrugs as Anticancer Agents

14:37 EDT 12 Jul 2018 | NIH

Poly-ADP ribose polymerase-1 (PARP-1) is a critical enzyme involved in DNA repair.  The inhibition of PARP has emerged as a promising strategy in cancer therapy.  Numerous PARP inhibitors have been developed and advanced into clinical trials, both for use as single agents in specific patient populations and as combination therapies with various chemotherapeutics.  The induction of strand break damage to DNA, as has been demonstrated in cancer cells treated with O2-arylated diazeniumdiolates, coupled with inhibition of DNA repair by PARP inhibitors, represents a novel rationale for effective combination therapy.

Scientists at NCI developed prodrugs that combine structural features of the known PARP inhibitor olaparib  with an O2-arylated diazeniumdiolate in one hybrid molecule.  The two-component prodrug has the advantage of delivering both a DNA damaging agent (NO) and an inhibitor of DNA repair (PARP inhibitor) simultaneously to a cancer cell.  The prodrugs are activated by glutathione (GSH) and the reaction accelerated by glutathione S-transferase P1 (GSTP1), an enzyme frequently overexpressed in cancer.  This mechanism consumes GSH while releasing cytotoxic NO and a PARP inhibitor simultaneously in the target cancer cell.  As high levels of GSH/GSTP1 are often a feature of cancer cells, the compound is predicted to have strong synergy with other anticancer therapeutics. When compared to the PARP inhibitor olaparib, these hybrid molecules exceeded the in vivo anticancer potency in xenograft models, resulting in more extensive DNA strand break damage, and ultimately greater apoptosis induction, as observed in vitro. These compounds are predicted to have strong radio- and chemosensitizing effects.

NIH Ref. No.: 
E-220-2011
Advantages: 
  • Combination of a DNA damaging agent and a DNA repair inhibitor in one molecule eliminates the need to administer two separate treatments;
  • Activation mechanism that involves overexpressed in cancers GSTP1 targets drugs to cancer cell
Applications: 
  • Stand-alone cancer therapeutics or as part of a combination therapy with other cancer therapies
Development Status: 

Pre-clinical (in vivo)

Updated On: 
May 30, 2018
Provider Classifications: 
Publications: 
Licensing Contacts: 
Lead Inventor: 
LPM FIrst Name: 
John
LPM Last Name: 
Hewes
Inv Is lead: 
LPM Phone: 
240-276-5515
LPM Suffix: 
Ph.D.
LPM Organization: 
NCI - National Cancer Institute
DTDT Classification: 
Therapeutics
DTDT Description: 
Therapeutics
Collaboration Sought: 
Yes
Collaboration Opportunity: 

Licensing only

E Number Only: 
E-220-2011
Inventor First Name: 
Anna
Joseph
Larry
Inventor Last Name: 
Maciag
Saavedra
Keefer

Original Article: PARP Inhibitor and NO-Donor Dual Prodrugs as Anticancer Agents

NEXT ARTICLE

More From BioPortfolio on "PARP Inhibitor and NO-Donor Dual Prodrugs as Anticancer Agents"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Polymerase Chain Reaction (PCR)
PCR (Polymerase Chain Reaction) uses the ability of DNA polymerase (enzymes that create DNA molecules by assembling nucleotides, the building blocks of DNA. These enzymes are essential to DNA replication and usually work in pairs to create two ident...

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...